Novo Nordisk, Altimmune, SelectQuote, Spectrum Pharma face class action lawsuits.

Bragar Eagel & Squire, a shareholder rights law firm, has filed class action lawsuits on behalf of investors in Novo Nordisk A/S, Altimmune, Inc., SelectQuote, Inc., and Spectrum Pharmaceuticals, Inc. The lawsuits allege that the companies made false and misleading statements about their growth potential and performance. Investors have until September 30, 2025, to petition the court to serve as lead plaintiff.

Investors in Novo Nordisk A/S, Altimmune, Inc., SelectQuote, Inc., and Spectrum Pharmaceuticals, Inc. are advised to review recent class action lawsuits filed against these companies. These lawsuits allege that the companies made false and misleading statements about their growth potential and performance, potentially resulting in significant financial losses for investors.

The lawsuits, initiated by Bragar Eagel & Squire, a prominent shareholder rights law firm, allege various forms of securities fraud and misrepresentation. Investors who purchased or acquired securities in these companies during the specified class periods are encouraged to review the details of these lawsuits and consider their legal rights.

For Novo Nordisk A/S (NYSE: NVO), the class action lawsuit alleges misrepresentations regarding the company's growth potential stemming from its diabetes/obesity drug, GLP-1. The lawsuit claims that the company made false statements between May 7, 2025, and July 28, 2025 [2].

Altimmune, Inc. (NASDAQ: ALT) investors are also targeted in a class action lawsuit. The complaint alleges securities fraud between August 10, 2023, and June 25, 2025. The lawsuit follows Altimmune's announcement of results from the IMPACT Phase 2b MASH trial of Pemvidutide, which did not meet statistical significance, leading to a significant decline in the company's stock price [3].

SelectQuote, Inc. (NYSE: SLQT) investors are reminded of a class action lawsuit filed on behalf of those who purchased SelectQuote securities between September 9, 2020, and May 1, 2025. The complaint alleges violations of the False Claims Act, including directing Medicare beneficiaries to plans based on kickbacks and failing to provide unbiased comparison shopping [4].

Spectrum Pharmaceuticals, Inc. investors are also involved in a class action lawsuit. The case, initiated by Bragar Eagel & Squire, alleges misleading statements made by the company [2].

Investors have until September 30, 2025, to petition the court to serve as lead plaintiffs in these lawsuits. It is recommended that affected shareholders act promptly and consult with legal professionals specializing in securities law for further guidance.

References:
[1] https://www.globenewswire.com/news-release/2025/08/29/3141574/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Reminds-Investors-with-Losses-on-their-Investment-in-Novo-Nordisk-A-S-of-Class-Action-Lawsuit-and-Upcoming-Deadlines-NVO.html
[2] https://www.ainvest.com/news/novo-nordisk-altimmune-selectquote-spectrum-pharmaceuticals-face-class-action-lawsuits-2508/
[3] https://www.marketscreener.com/news/altimmune-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-befor-ce7c50d9db8fff27
[4] https://www.globenewswire.com/news-release/2025/08/29/3141679/32716/en/Investors-Sue-SelectQuote-SLQT-After-DOJ-Intervenes-in-Kickback-Lawsuit-Hagens-Berman.html